Cargando…

Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer

Cancer cell plasticity due to the dynamic architecture of interactome networks provides a vexing outlet for therapy evasion. Here, through chemical biology approaches for systems level exploration of protein connectivity changes applied to pancreatic cancer cell lines, patient biospecimens, and cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Suhasini, Gomes, Erica DaGama, Wang, Tai, Corben, Adriana, Taldone, Tony, Gandu, Srinivasa, Xu, Chao, Sharma, Sahil, Buddaseth, Salma, Yan, Pengrong, Chan, Lon Yin L., Gokce, Askan, Rajasekhar, Vinagolu K., Shrestha, Lisa, Panchal, Palak, Almodovar, Justina, Digwal, Chander S., Rodina, Anna, Merugu, Swathi, Pillarsetty, NagaVaraKishore, Miclea, Vlad, Peter, Radu I., Wang, Wanyan, Ginsberg, Stephen D., Tang, Laura, Mattar, Marissa, de Stanchina, Elisa, Yu, Kenneth H., Lowery, Maeve, Grbovic-Huezo, Olivera, O’Reilly, Eileen M., Janjigian, Yelena, Healey, John H., Jarnagin, William R., Allen, Peter J., Sander, Chris, Erdjument-Bromage, Hediye, Neubert, Thomas A., Leach, Steven D., Chiosis, Gabriela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617294/
https://www.ncbi.nlm.nih.gov/pubmed/34824367
http://dx.doi.org/10.1038/s42003-021-02842-3
_version_ 1784604492614860800
author Joshi, Suhasini
Gomes, Erica DaGama
Wang, Tai
Corben, Adriana
Taldone, Tony
Gandu, Srinivasa
Xu, Chao
Sharma, Sahil
Buddaseth, Salma
Yan, Pengrong
Chan, Lon Yin L.
Gokce, Askan
Rajasekhar, Vinagolu K.
Shrestha, Lisa
Panchal, Palak
Almodovar, Justina
Digwal, Chander S.
Rodina, Anna
Merugu, Swathi
Pillarsetty, NagaVaraKishore
Miclea, Vlad
Peter, Radu I.
Wang, Wanyan
Ginsberg, Stephen D.
Tang, Laura
Mattar, Marissa
de Stanchina, Elisa
Yu, Kenneth H.
Lowery, Maeve
Grbovic-Huezo, Olivera
O’Reilly, Eileen M.
Janjigian, Yelena
Healey, John H.
Jarnagin, William R.
Allen, Peter J.
Sander, Chris
Erdjument-Bromage, Hediye
Neubert, Thomas A.
Leach, Steven D.
Chiosis, Gabriela
author_facet Joshi, Suhasini
Gomes, Erica DaGama
Wang, Tai
Corben, Adriana
Taldone, Tony
Gandu, Srinivasa
Xu, Chao
Sharma, Sahil
Buddaseth, Salma
Yan, Pengrong
Chan, Lon Yin L.
Gokce, Askan
Rajasekhar, Vinagolu K.
Shrestha, Lisa
Panchal, Palak
Almodovar, Justina
Digwal, Chander S.
Rodina, Anna
Merugu, Swathi
Pillarsetty, NagaVaraKishore
Miclea, Vlad
Peter, Radu I.
Wang, Wanyan
Ginsberg, Stephen D.
Tang, Laura
Mattar, Marissa
de Stanchina, Elisa
Yu, Kenneth H.
Lowery, Maeve
Grbovic-Huezo, Olivera
O’Reilly, Eileen M.
Janjigian, Yelena
Healey, John H.
Jarnagin, William R.
Allen, Peter J.
Sander, Chris
Erdjument-Bromage, Hediye
Neubert, Thomas A.
Leach, Steven D.
Chiosis, Gabriela
author_sort Joshi, Suhasini
collection PubMed
description Cancer cell plasticity due to the dynamic architecture of interactome networks provides a vexing outlet for therapy evasion. Here, through chemical biology approaches for systems level exploration of protein connectivity changes applied to pancreatic cancer cell lines, patient biospecimens, and cell- and patient-derived xenografts in mice, we demonstrate interactomes can be re-engineered for vulnerability. By manipulating epichaperomes pharmacologically, we control and anticipate how thousands of proteins interact in real-time within tumours. Further, we can essentially force tumours into interactome hyperconnectivity and maximal protein-protein interaction capacity, a state whereby no rebound pathways can be deployed and where alternative signalling is supressed. This approach therefore primes interactomes to enhance vulnerability and improve treatment efficacy, enabling therapeutics with traditionally poor performance to become highly efficacious. These findings provide proof-of-principle for a paradigm to overcome drug resistance through pharmacologic manipulation of proteome-wide protein-protein interaction networks.
format Online
Article
Text
id pubmed-8617294
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-86172942021-12-10 Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer Joshi, Suhasini Gomes, Erica DaGama Wang, Tai Corben, Adriana Taldone, Tony Gandu, Srinivasa Xu, Chao Sharma, Sahil Buddaseth, Salma Yan, Pengrong Chan, Lon Yin L. Gokce, Askan Rajasekhar, Vinagolu K. Shrestha, Lisa Panchal, Palak Almodovar, Justina Digwal, Chander S. Rodina, Anna Merugu, Swathi Pillarsetty, NagaVaraKishore Miclea, Vlad Peter, Radu I. Wang, Wanyan Ginsberg, Stephen D. Tang, Laura Mattar, Marissa de Stanchina, Elisa Yu, Kenneth H. Lowery, Maeve Grbovic-Huezo, Olivera O’Reilly, Eileen M. Janjigian, Yelena Healey, John H. Jarnagin, William R. Allen, Peter J. Sander, Chris Erdjument-Bromage, Hediye Neubert, Thomas A. Leach, Steven D. Chiosis, Gabriela Commun Biol Article Cancer cell plasticity due to the dynamic architecture of interactome networks provides a vexing outlet for therapy evasion. Here, through chemical biology approaches for systems level exploration of protein connectivity changes applied to pancreatic cancer cell lines, patient biospecimens, and cell- and patient-derived xenografts in mice, we demonstrate interactomes can be re-engineered for vulnerability. By manipulating epichaperomes pharmacologically, we control and anticipate how thousands of proteins interact in real-time within tumours. Further, we can essentially force tumours into interactome hyperconnectivity and maximal protein-protein interaction capacity, a state whereby no rebound pathways can be deployed and where alternative signalling is supressed. This approach therefore primes interactomes to enhance vulnerability and improve treatment efficacy, enabling therapeutics with traditionally poor performance to become highly efficacious. These findings provide proof-of-principle for a paradigm to overcome drug resistance through pharmacologic manipulation of proteome-wide protein-protein interaction networks. Nature Publishing Group UK 2021-11-25 /pmc/articles/PMC8617294/ /pubmed/34824367 http://dx.doi.org/10.1038/s42003-021-02842-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Joshi, Suhasini
Gomes, Erica DaGama
Wang, Tai
Corben, Adriana
Taldone, Tony
Gandu, Srinivasa
Xu, Chao
Sharma, Sahil
Buddaseth, Salma
Yan, Pengrong
Chan, Lon Yin L.
Gokce, Askan
Rajasekhar, Vinagolu K.
Shrestha, Lisa
Panchal, Palak
Almodovar, Justina
Digwal, Chander S.
Rodina, Anna
Merugu, Swathi
Pillarsetty, NagaVaraKishore
Miclea, Vlad
Peter, Radu I.
Wang, Wanyan
Ginsberg, Stephen D.
Tang, Laura
Mattar, Marissa
de Stanchina, Elisa
Yu, Kenneth H.
Lowery, Maeve
Grbovic-Huezo, Olivera
O’Reilly, Eileen M.
Janjigian, Yelena
Healey, John H.
Jarnagin, William R.
Allen, Peter J.
Sander, Chris
Erdjument-Bromage, Hediye
Neubert, Thomas A.
Leach, Steven D.
Chiosis, Gabriela
Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer
title Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer
title_full Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer
title_fullStr Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer
title_full_unstemmed Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer
title_short Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer
title_sort pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617294/
https://www.ncbi.nlm.nih.gov/pubmed/34824367
http://dx.doi.org/10.1038/s42003-021-02842-3
work_keys_str_mv AT joshisuhasini pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT gomesericadagama pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT wangtai pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT corbenadriana pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT taldonetony pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT gandusrinivasa pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT xuchao pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT sharmasahil pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT buddasethsalma pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT yanpengrong pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT chanlonyinl pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT gokceaskan pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT rajasekharvinagoluk pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT shresthalisa pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT panchalpalak pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT almodovarjustina pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT digwalchanders pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT rodinaanna pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT meruguswathi pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT pillarsettynagavarakishore pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT micleavlad pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT peterradui pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT wangwanyan pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT ginsbergstephend pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT tanglaura pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT mattarmarissa pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT destanchinaelisa pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT yukennethh pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT lowerymaeve pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT grbovichuezoolivera pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT oreillyeileenm pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT janjigianyelena pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT healeyjohnh pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT jarnaginwilliamr pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT allenpeterj pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT sanderchris pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT erdjumentbromagehediye pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT neubertthomasa pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT leachstevend pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer
AT chiosisgabriela pharmacologicallycontrollingproteinproteininteractionsthroughepichaperomesfortherapeuticvulnerabilityincancer